RecruitingNot ApplicableNCT06183359

Self-Identification Program

Correct Self-identification Program in the Treatment of Depression: a Randomized Controlled Trial


Sponsor

University Hospital, Montpellier

Enrollment

86 participants

Start Date

Aug 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Conduct a pilot, single-center, randomized controlled 2-arm study aimed to evaluate the impact of an in-depth 3rd wave CBT program targeting correct self-identification (3rd level of 3rd wave CBT), compared to a control group receiving an acceptance and commitment therapy (ACT; (1st level of 3rd wave CBT, a well-known psychotherapy). Main judgment criteria : Therapeutic response (reduction ≥ 50% between pre and immediate post-treatment), and rate of relapse at 6 months post-therapy. Secondary objectives: Evaluate psychological processes involved in the reduction of moral pain, diligence, ruminations, suicidal ideas, self-concept and alterations in functioning (mental and social), psychological skills.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria1

  • Patients aged 18 to 70 years, presenting a current major depressive episode (according to DSM 571), as part of unipolar or bipolar depressive disorder

Exclusion Criteria9

  • Patients with a psychotic disorder
  • Patients with active thoughts of suicide with intention to carry out the act (C-SSRS "ideation suicidal" in the last week ≥ 4)
  • Inability to receive informed information about the study
  • Exclusion period determined by a previous study
  • Adult protected by law or patient under guardianship or curatorship
  • Not be affiliated to a French social security scheme or beneficiary of such a scheme
  • Not being able to give informed written consent
  • Pregnant or breastfeeding women
  • Patients under judicial protection

Interventions

OTHERSIP

compare the SIP group versus the ACT group


Locations(1)

CHU Montpellier

Montpellier, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06183359


Related Trials